Indication
In combination with ipilimumab for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma.

Medicine details

Medicine name:
nivolumab (Opdivo)
SMC ID:
SMC2153
Pharmaceutical company
Bristol-Myers Squibb Pharmaceuticals Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Status
Advice due date:
10 June 2019
SMC meeting date:
07 May 2019
Patient group submission deadline:
01 April 2019